Adebrelimab Injection

Adebelimumab injection can block the PD-1/PD-L1 pathway that causes tumor immune tolerance by specifically binding to the PD-L1 molecule, reactivating the anti-tumor activity of the immune system, thereby achieving the purpose of treating tumors. It can be used in combination with carboplatin and etoposide for the first-line treatment of patients with extensive-stage small cell lung cancer, providing a new treatment option for patients with small cell lung cancer.